pha 665 752  (TargetMol)

Journal: Biochimica et biophysica acta. Molecular cell research

Article Title: Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

doi: 10.1016/j.bbamcr.2025.120001

Figure Lengend Snippet: Fig. 2. Stimulation of STAT3-BCL2 axis by AURKB. (A) Gene set enrichment (GSEA) data of upregulated STAT3 target genes in the H1993 PR-S2 cells. (B) Protein expressions of p-STAT3, STAT3, and GAPDH. (C) Protein expressions of p-STAT3, STAT3, p-AURKB, AURKB, and GAPDH after barasertib single or PHA665752 combination treatment of indicated drug concentration for 48 h. (D) Immunoblot analysis of the H1993 and H1993 PR-S2 cells transfected with scramble and siAURKB for 48 h. (E) and (F) The indicated protein ex pressions of the GFP and AURKB-GFP virus-infected H1993 stable cell lines and MG132 treatment for the indicated treatment time. The line graph represents the protein stability of p-STAT3. (G) and (H) RT-qPCR and immunoblotting measured the expressions of STAT3 downstream targets. (I) mRNA expression of BCL2 after treatment of 10, 100, and 1000 nM concentrations of barasertib. (J) mRNA expression levels of BCL2 and STAT3 in the scramble or siSTAT3 transfected H1993 and H1993 PR-S2 cells. (K) Protein expression of cleaved-caspase3 and BCL2 after treatment with barasertib for 48 h. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.

Article Snippet: PHA665752, barasertib, VX680, MLN8237, AT9283, cycloheximide, and MG132 were purchased from Selleckchem Korea (Seoul, Korea).

Techniques: Concentration Assay, Western Blot, Transfection, Virus, Infection, Stable Transfection, Quantitative RT-PCR, Expressing

Journal: Biochimica et biophysica acta. Molecular cell research

Article Title: Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

doi: 10.1016/j.bbamcr.2025.120001

Figure Lengend Snippet: Fig. 3. Induced apoptotic cell death by AURKB inhibition. (A) RT-qPCR measured the mRNA expression of apoptosis-related genes in the H1993 and H1993 PR-S2 cells. (B) Western blot analysis after treatment PHA665752 or barasertib (each 1 uM) for 48 h. The bar graph represents the band intensity of BIMEL. (C) The activated form expression of BIM protein (S69 and S87) in the H1993 and H1993 PR-S2 cells. (D) Histogram indicated cell cycles of the H1993 and H1993 PR-S2 cells after AURKB inhibitor dose-dependent treatment for 24 h. The bar graph indicates the cell cycle proportion of G1, S, and G2/M. (E) Annexin-V-FITC/PI flow cytometry analysis of the H1993 and H1993 PR-S2 cells treated with 100, 250, and 500 nM of barasertib for 48 h. The bar graph represents the early and late apoptotic cell population of the barasertib-treated H1993 and H1993 PR-S2 cells. (F) Immunofluorescence analysis of nucleus (blue) and cleaved-caspase3 (green) after treatment with barasertib. Scale bars, 100 μm. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001, Abbre viation: Bara, Barasertib. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: PHA665752, barasertib, VX680, MLN8237, AT9283, cycloheximide, and MG132 were purchased from Selleckchem Korea (Seoul, Korea).

Techniques: Inhibition, Quantitative RT-PCR, Expressing, Western Blot, Flow Cytometry, Immunofluorescence

Journal: Biochimica et biophysica acta. Molecular cell research

Article Title: Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition.

doi: 10.1016/j.bbamcr.2025.120001

Figure Lengend Snippet: Fig. 4. AURKB inhibition effect in xenograft model. (A) Diagram summarizing xenograft experiment strategy in NOD-2/Shi-scid IL2rgamma(null) (N2G) mice. (B) and (C) The measurement of tumor volume (mm3) following treatment with vehicle, PHA665752 (25 mg/kg), Barasertib (50 mg/kg) and their combination for 21 days in N2G mice bearing the H1993 and H1993 PR- S2 cell xenografts. Tumor volumes were measured twice weekly by caliper (mean ± SEM, n = 6–7 for each group). (D) The fold change of the tumor volume during the period of drug injection, representing 0, 6, 14, 16, 18, and 20 days. (E) Representative hematoxylin and eosin (H&E) and Ki-67 staining images of xenograft tumors. Scale bars, 100 μm. The bar graph indicates the relative percentage of the Ki-67-positive cells. The error bars represent the mean ± SEM (n = 3). Statistical analysis was performed using a two-sample t-test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001, Abbreviation: PHA, PHA665752; Bara, Barasertib.

Article Snippet: PHA665752, barasertib, VX680, MLN8237, AT9283, cycloheximide, and MG132 were purchased from Selleckchem Korea (Seoul, Korea).

Techniques: Inhibition, Injection, Staining